

Impact of *HKDC1* genetic variants on gestational diabetes and hypothyroidism in pregnancy: a pilot study

Katarzyna Gawlik^{1*}, Tomasz Milewicz², Barbara Zapata³, Dorota Pawlica-Gosiewska¹, Monika Piwowar⁴, Bogdan Solnica¹

¹Department of Clinical Biochemistry, Jagiellonian University Medical College, Krakow, Poland

²Department of Gynecological Endocrinology, Jagiellonian University Medical College, Krakow, Poland

³Center for Innovative Medical Education, Jagiellonian University Medical College, Krakow, Poland

⁴Department of Bioinformatics and Telemedicine, Jagiellonian University Medical College, Krakow, Poland

***Corresponding author:**

Katarzyna Gawlik
Department of
Clinical Biochemistry
Jagiellonian University
Medical College
Krakow, Poland
E-mail: k.gawlik@uj.edu.pl

Submitted: 20 March 2025; **Accepted:** 30 May 2025

Online publication: 24 June 2025

Arch Med Sci 2026; 22 (3): 1787–1793

DOI: <https://doi.org/10.5114/aoms/205736>

Copyright © 2025 Termedia & Banach

Abstract

Introduction: Gestational diabetes mellitus (GDM) and hypothyroidism are common pregnancy-related disorders that may have a genetic background. The hexokinase domain containing 1 (*HKDC1*) gene is involved in glucose metabolism, and its variants may influence thyroid function by modulating metabolic pathways. This interaction could contribute to the development of thyroid dysfunction.

Material and methods: A total of 20 healthy pregnant controls, 20 pregnant women with GDM, and 19 pregnant women with hypothyroidism were genotyped for the *HKDC1* gene polymorphisms rs1076224, rs4746822, rs2394529, and rs9645501.

Results: Statistically significant differences were found in the genotype distribution of the *HKDC1* rs1076224 polymorphism in the dominant model (G/G vs. A/G + A/A) between women with and without GDM ($p = 0.039$). Additionally, the *HKDC1* rs4746822 polymorphism showed significant differences in both the codominant ($p = 0.044$) and overdominant ($p = 0.014$) models between hypothyroid and non-hypothyroid pregnant women. The rs2394529 polymorphism also demonstrated significant differences in the overdominant model (C/C + G/G vs. C/G, $p = 0.032$) between hypothyroid and non-hypothyroid groups. However, no differences were observed in the genotype or allele frequencies of the *HKDC1* rs9645501 variant across the study groups.

Conclusions: This study suggests a potential genetic association between *HKDC1* polymorphisms and the risk of GDM and hypothyroidism in pregnancy. The findings highlight rs1076224 as a significant marker for GDM susceptibility, and rs4746822 and rs2394529 as potential markers for hypothyroidism. Further large-scale studies are needed to confirm these associations and understand their clinical implications.

Key words: pregnancy, gestational diabetes mellitus (GDM), hypothyroidism, hexokinase domain containing 1 gene (*HKDC1*), single nucleotide polymorphism (SNP).

Introduction

Pregnancy is a period associated with significant physiological changes that are mainly caused by changes in hormone levels [1]. Hormonal changes during pregnancy may affect both glucose metabolism and thyroid function [2].

Gestational diabetes mellitus (GDM) and gestational thyroid dysfunction (GTD) are the two most prevalent endocrinopathies during pregnancy [3]. GDM is a form of hyperglycemia diagnosed for the first time during pregnancy [4]. The International Association of Diabetes and Pregnancy Study Groups (IADPSG) estimates the global prevalence of GDM as 14% of pregnant women, with a significant continuously increasing trend [5]. The main pathogenetic mechanism in the development of GDM is insufficient insulin secretion relative to the physiological insulin resistance (IR) that occurs during pregnancy [4]. Known risk factors for GDM include overweight and obesity [6], advanced maternal age [7], and a family history of glucose intolerance or diabetes [8].

Hypothyroidism is the second most prevalent endocrine disorder during pregnancy, following GDM. Its prevalence ranges from 3% to 5% [9]. The most common causes of hypothyroidism are iodine deficiency and chronic autoimmune thyroiditis, particularly Hashimoto's disease [10]. Both thyroid dysfunction and GDM can lead to serious maternal and fetal complications if not adequately diagnosed and treated. Uncontrolled hypothyroidism may lead to miscarriage, maternal anemia, pre-eclampsia, and placental abnormalities [2]. GDM increases the risk of preterm birth, macrosomia, and fetal distress. It also increases the risk of diabetes in both the mother and the offspring [11].

In recent years, several studies have reported associations between single nucleotide polymorphisms (SNPs) in various genes and the risk of selected diseases [12–15].

The hexokinase domain containing 1 (*HKDC1*) gene encodes a protein belonging to the hexokinase family, which plays a crucial role in glucose metabolism [16]. Unlike other hexokinases (e.g., *HK1*–*HK4*), which are well-characterized enzymes involved in phosphorylating glucose during glycolysis [17], *HKDC1* is less studied, and its precise enzymatic activity remains unclear.

Recent studies have shown that *HKDC1* may influence glucose homeostasis, insulin sensitivity, and hepatic glucose regulation [18]. Genetic variants in *HKDC1* have been associated with altered glucose tolerance and an increased risk of developing GDM, particularly in late pregnancy [19]. Additionally, *HKDC1* expression is elevated in insulin-resistant states, indicating

a possible role in metabolic adaptation during pregnancy [18].

Functional studies have demonstrated that reduced *HKDC1* expression impairs glucose tolerance and increases hepatic glucose output, while hepatic overexpression improves glucose metabolism in pregnant mouse models [18]. These experimental findings are supported by genome-wide association studies (GWAS), which have identified SNPs in *HKDC1* (such as rs4746822 and rs1076224) associated with fasting glucose levels [20].

Despite its structural similarity to classical hexokinases, *HKDC1* has low enzymatic activity, suggesting a potential regulatory rather than catalytic role in glucose metabolism [21].

Although *HKDC1* has been established as relevant in GDM and related metabolic pathways, there is currently no evidence linking this gene to hypothyroidism. Its potential role in thyroid pathophysiology remains unexplored.

The aim of this study was to investigate the association between *HKDC1* SNPs (rs4746822, rs1076224, rs2394529, rs9645501) and the risk of GDM and hypothyroidism in pregnant women, to better understand their potential role in metabolic and hormonal dysregulation during pregnancy.

Material and methods

Subjects

This case-control study included 59 pregnant women in their third trimester (28–36 weeks of gestation). The participants were divided into three groups: 20 healthy pregnant women (without GDM or hypothyroidism), 20 pregnant women diagnosed with GDM, and 19 with hypothyroidism.

The diagnosis of GDM was based on a 75-gram oral glucose tolerance test conducted between 24 and 28 weeks of gestation, according to the IADPSG criteria [22]. GDM was diagnosed if any of the following plasma glucose values were met or exceeded: fasting glucose ≥ 92 mg/dl (≥ 5.1 mmol/l), 1-hour glucose ≥ 180 mg/dl (≥ 10.0 mmol/l), or 2-hour glucose between 153 and 199 mg/dl (8.5–11.0 mmol/l) [13]. Hypothyroidism was diagnosed when TSH levels exceeded 2.5 μ U/l in the first trimester of pregnancy [23].

Women with pregestational diabetes (type 1 or type 2), pre-pregnancy hypothyroidism, or autoimmune diseases unrelated to thyroid or glucose metabolism were not included in the study.

Methods

Blood samples were collected from all study participants. Approximately 5 ml of whole blood was collected in EDTA tubes. Genomic DNA was manually isolated using the commercially available QIAamp DNA Blood Mini Kit (Qiagen, Valen-

cia, CA, USA), which is based on silica-membrane spin columns. The quantity and quality of DNA samples were assessed using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) and a Qubit 4 Fluorometer (Thermo Fisher Scientific, USA). Only high-quality DNA was used for genotyping. All eluates were stored at -20°C until genotype analysis. For the analysis, ready-to-order Custom TaqMan SNP Genotyping Assays (Applied Biosystems, USA) were used. Genotyping of selected single nucleotide polymorphisms (SNPs) – rs1076224, rs4746822, rs2394529, and rs9645501 – in the *HKDC1* gene was performed using commercially available, ready-to-use TaqMan probe kits, specifically the Sample-to-SNP Kit (Applied Biosystems, USA). The assay kit included a pair of primers and two differently labeled TaqMan minor groove binder (MGB) probes for allele discrimination. The probes were labeled with FAM and VIC dyes at the 5' end and contained MGB molecules along with a non-fluorescent quencher (NFQ) at the 3' end. A total of 20 ng of genomic DNA was used for amplification in a 25 μl reaction mix. Polymerase chain reaction (PCR) was performed according to the manufacturer's instructions provided by Applied Biosystems. The PCR-based amplification followed the thermal cycling conditions: initial denaturation at 95°C for 30 s, followed by 40 cycles of 92°C for 5 s and 60°C for 20 s. Amplicons were then analyzed using an Applied Biosystems ViiA 7 Real-Time PCR System, and genotype calls were determined manually by comparison with no-template controls. Homozygosity for FAM or VIC-specific alleles (X:X or Y:Y) was confirmed by an increase in fluorescence of either FAM or VIC dye. An increase in fluorescence from both dyes indicated heterozygosity (X:Y). The two dyes (FAM and VIC) were detected using the ViiA 7 Real-Time PCR System. Genotype calls were assessed using the Applied Biosystems TaqMan Genotyper Software.

Statistical analysis

The raw fluorescence data generated by PCR amplification were converted into specific alleles and genotypes. The metadata were then correlated with the obtained genotypes. The genotype distribution and allele frequencies of selected SNPs in the *HKDC1* gene were compared between the control and study groups using the χ^2 test. Bon-

ferroni's post hoc test was applied to determine differences between the groups. Hardy-Weinberg equilibrium was assessed using a goodness-of-fit χ^2 test. The Kruskal-Wallis test was used in R to compare the observed and expected genotype distributions across the groups. Statistical significance was defined as p -values < 0.05 .

Statistical analysis was performed using Microsoft Excel 2019 within the R version 3.5.5 statistical environment and the PSPP program.

Results

All SNPs were in Hardy-Weinberg equilibrium (HWE) ($p > 0.05$) in both the case and control groups.

Genotype and allele frequencies of the *HKDC1* rs1076224 variant

In this study, we identified statistically significant differences in the distribution of genotypes in the *HKDC1* rs1076224 dominant model (G/G vs. A/G + A/A) between pregnant women with and without GDM, with an odds ratio (OR) of 0.19 (95% CI: 0.04–1.06). The A/G and A/A genotypes were observed more frequently in the group without GDM. Individuals with the G/G genotype did not exhibit a significantly increased or decreased risk for GDM compared to the other groups (Table I).

Genotype and allele frequencies of the *HKDC1* rs4746822 variant

This study revealed statistically significant differences in the genotype distribution of the *HKDC1* rs4746822 codominant model (T/T, C/T, and C/C) between pregnant women with hypothyroidism and those without ($p = 0.044$). The T/T genotype was associated with a lower risk of hypothyroidism, whereas the C/T genotype was linked to an increased risk. The risk for individuals with the C/C genotype remained unclear due to the limited data, as only 4 cases were observed. The T allele was associated with a lower risk of hypothyroidism, while the C allele, particularly in the heterozygous C/T configuration, may increase the risk (Table II).

Significant differences were also observed between pregnant women with and without hypothyroidism in the *HKDC1* rs4746822 overdominant model (T/T + C/C- compared to C/T) ($p = 0.014$).

Table I. Evaluation of the relationship between the rs1076224 polymorphism of the *HKDC1* gene and the incidence of GDM ($N = 40$)

Model	Genotype	Control group (%)	GDM (%)	OR (95% CI)	P-value
Dominant	G/G	2 (10)	8 (36.4)	1.00	0.039
	A/G+A/A	18 (90)	14 (63.6)	0.19 (0.04–1.06)	

P-values (statistical significance) were calculated using the χ^2 test, OR – odds ratio, CI – confidence interval.

Table II. Evaluation of the relationship between the rs4746822 polymorphism of the *HKDC1* gene and the incidence of HT (*N* = 39)

Model	Genotype	Control group (%)	HT (%)	OR (95% CI)	P-value
Codominant	T/T	13 (65)	7 (36.8)	1.00	0.044
	C/T	4 (20)	11 (57.9)	5.11 (1.18–22.16)	
	C/C	3 (15)	1 (5.3)	0.62 (0.05–7.12)	
Overdominant	T/T+C/C	16 (80)	8 (42.1)	1.00	0.014
	C/T	4 (20)	11 (57.9)	5.5 (1.32–22.86)	

P-values (statistical significance) were calculated using the χ^2 test, OR – odds ratio, CI – confidence interval.

Table III. Evaluation of the relationship between the rs2394529 polymorphism of the *HKDC1* gene and the incidence of HT (*N* = 39)

Model	Genotype	Control group (%)	HT (%)	OR (95% CI)	P-value
Overdominant	C/C+G/G	16 (80)	9 (47.4)	1.00	0.032
	C/G	4 (20)	10 (52.6)	4.44 (1.08–18.36)	

P-values (statistical significance) were calculated using the χ^2 test, OR – odds ratio, CI – confidence interval.

In a separate analysis, the heterozygous C/T genotype was associated with an increased risk of hypothyroidism (OR = 5.5, 95% CI: 1.32–22.86), whereas the homozygous C/C and T/T genotypes appeared to have a neutral effect on risk (Table II).

Genotype and allele frequencies of the *HKDC1* rs2394529 variant

This study found statistically significant differences in the genotype distribution of the *HKDC1* rs2394529 overdominant model (C/C + G/G vs. C/G) between pregnant women with and without hypothyroidism (*p* = 0.032). The presence of the C and G alleles in a heterozygous configuration (C/G) was associated with a 4.44-fold higher risk of hypothyroidism. No significant association was found between the homozygous genotypes (C/C and G/G) and disease risk (Table III).

Genotype and allele frequencies of the *HKDC1* rs9645501 variant

No differences were observed in the genotype and allele frequencies of the *HKDC1* rs9645501 variant among patients with GDM, hypothyroidism, and the control group.

Discussion

This study aimed to evaluate the association between specific regulatory variants of the *HKDC1* gene (rs1076224, rs4746822, rs2394529, and rs9645501) and the development of both gestational diabetes mellitus (GDM) and hypothyroidism during pregnancy. While previous research has examined the role of *HKDC1* single nucleotide polymorphisms (SNPs) in GDM [19], to our knowledge, this is the first study to explore their potential involvement in pregnancy-related hypothyroidism.

Our findings suggest that specific variants of the *HKDC1* gene are associated with GDM and hypothyroidism in pregnant women. In particular, a statistically significant association was observed between the *HKDC1* rs1076224 polymorphism and GDM. Additionally, rs4746822 and rs2394529 were significantly associated with hypothyroidism, while rs9645501 showed no differences in genotype or allele frequencies across the study groups. Among all four studied polymorphisms, associations were observed only for three, indicating distinct genetic contributions to different pregnancy-related metabolic and endocrine disorders. These results highlight the potential of *HKDC1* variants as biomarkers for such conditions.

In the dominant model (G/G vs. A/G + A/A) for the genotype distribution of *HKDC1* rs1076224, we observed that the A/G and A/A genotypes were more prevalent in the group without GDM (*p* = 0.039). These results suggest that the A allele may play a protective role in maintaining normal glucose metabolism during pregnancy, as women carrying at least one A allele (A/G or A/A) exhibited an 81% lower risk of developing GDM compared to those with the G/G genotype (OR = 0.19).

Currently, there is no clear evidence supporting a protective role of the A allele in *HKDC1* rs1076224 against diabetes. Most existing studies have focused on the role of the *HKDC1* gene in glucose metabolism and its association with diabetes risk [18, 19]. A study by Kanthimathi *et al.* reported a significant association between the rs1076224 variant and an increased risk of GDM, with an odds ratio of 1.24 [20]. However, replication studies conducted in Han Chinese [24] and Russian [25] populations did not confirm this association. These inconsistencies may reflect population-specific genetic backgrounds or environmental influences.

Protective roles for specific alleles against diabetes have been observed in other genes, such as *CREBRF* (rs373863828). A 2020 study demonstrated that the A allele of *CREBRF* is associated with reduced GDM prevalence in Māori and Pacific populations [26]. Furthermore, a 2021 study emphasized its role in enhancing insulin secretion without affecting insulin sensitivity, suggesting a potential mechanism for lowering type 2 diabetes risk [27]. Our findings raise the possibility that a similar protective mechanism may be involved in carriers of the A allele in *HKDC1* rs1076224.

Regarding the associations observed in hypothyroidism, we found significant relationships between the *HKDC1* rs4746822 and rs2394529 polymorphisms and thyroid dysfunction. In the co-dominant model (T/T, C/T, and C/C) for rs4746822, the T/T genotype was more common among healthy pregnant women compared to those with hypothyroidism, suggesting that the C allele may act as a potential risk factor for thyroid dysfunction. These findings may help identify individuals at increased risk of hypothyroidism. However, further studies with larger sample sizes are needed to confirm these findings and to elucidate the relationship between these SNPs and the risk of thyroid disease.

Additionally, in the overdominant model for both rs4746822 and rs2394529, the heterozygous C/T and C/G genotypes were associated with an increased risk of hypothyroidism. In contrast, homozygous genotypes (T/T, C/C, and G/G) appeared to have a neutral effect, suggesting that it is the combination of alleles in the heterozygous configuration, rather than the individual alleles themselves, that contributes to the observed risk.

Although data on *HKDC1* variants in thyroid disease are limited, similar heterozygote effects have been reported in other genes associated with autoimmune and endocrine disorders. For example, specific heterozygous combinations of *HLA* gene variants have been shown to increase susceptibility to autoimmune thyroid disease by disrupting antigen presentation or immune tolerance [28]. The +49A/G polymorphism (rs231775) in the *CTLA4* gene is another example, where the heterozygous A/G genotype is associated with an increased risk of autoimmune diseases, such as Hashimoto's thyroiditis and Graves' disease [29].

The mechanism behind the observed overdominant effect in *HKDC1* is unclear. Allele-specific interactions may disrupt *HKDC1* expression or related metabolic pathways in the thyroid. Given the role of *HKDC1* in glucose metabolism and energy regulation [16], altered expression could affect thyroid hormone synthesis or immune responses. This hypothesis requires confirmation in functional studies.

Although *HKDC1* is primarily involved in glucose metabolism [16], our study is the first to suggest a potential link between *HKDC1* polymorphisms and hypothyroidism during pregnancy. Previous studies have identified other SNPs associated with thyroid dysfunction [13, 30], but no data are currently available regarding the role of *HKDC1* variants in thyroid disease. This gene is not known to directly regulate thyroid function; however, its role in metabolic processes [31] may indirectly influence thyroid health, particularly during pregnancy when the endocrine and metabolic systems are tightly interlinked [3]. Further research is required to elucidate the molecular mechanisms by which these genetic variants contribute to thyroid dysfunction. Understanding these interactions could improve early detection and management strategies for metabolic and thyroid disorders in pregnant women, potentially reducing the risks for both maternal and fetal health.

In conclusion, the results of this study reveal a significant association between *HKDC1* gene polymorphisms (rs1076224, rs4746822, and rs2394529) and both gestational diabetes mellitus and hypothyroidism during pregnancy. These findings suggest a potential genetic link between *HKDC1*, previously implicated in glucose metabolism, and thyroid dysfunction in pregnancy, providing novel insights into the genetic factors that may contribute to the susceptibility of pregnant women to these conditions.

This preliminary study has several limitations. First, the small sample size limits statistical power and may affect the reliability and generalizability of the findings. Second, the single-center design introduces potential selection bias and may not adequately reflect other demographic or geographic groups. Third, no functional studies were conducted to assess the biological mechanisms behind the associations between *HKDC1* variants and the studied conditions, so the molecular relevance of these polymorphisms remains speculative. Fourth, the study did not account for potential confounding factors such as body mass index (BMI), smoking status, dietary habits, or other environmental and lifestyle factors, which may influence both glucose metabolism and thyroid function during pregnancy. Finally, due to the cross-sectional design, no conclusions can be drawn about the temporal relationship between genetic variants and disease onset.

Future studies with larger and more diverse cohorts, comprehensive clinical data, and functional analyses are needed to provide deeper insights into the role of *HKDC1* in pregnancy-related endocrine disorders.

Funding

No external funding.

Ethical approval

The study was approved by the Bioethics Committee of the Jagiellonian University (No: 1072.6120.286.2020). Informed consent was obtained from all the subjects involved in the study.

Conflict of interest

The authors declare no conflict of interest.

References

1. Kepley JM, Bates K, Mohiuddin SS. Physiology, Maternal Changes. 2023 Mar 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
2. Yanachkova V, Kamenov Z. The relationship between thyroid dysfunction during pregnancy and gestational diabetes mellitus. *Endokrynol Pol* 2021; 72: 226-31.
3. Pinto S, Croce L, Carlier L, Cosson E, Rotondi M. Thyroid dysfunction during gestation and gestational diabetes mellitus: a complex relationship. *J Endocrinol Invest* 2023; 46: 1737-59.
4. Johns EC, Denison FC, Norman JE, Reynolds RM. Gestational diabetes mellitus: mechanisms, treatment, and complications. *Trends Endocrinol Metab* 2018; 29: 743-54.
5. Wang H, Li N, Chivese T, et al. IDF Diabetes Atlas Committee Hyperglycaemia in Pregnancy Special Interest Group. IDF Diabetes Atlas: Estimation of Global and Regional Gestational Diabetes Mellitus Prevalence for 2021 by International Association of Diabetes in Pregnancy Study Group's Criteria. *Diabetes Res Clin Pract* 2022; 183: 109050.
6. Okosun IS, Chandra KM, Boev A, et al. Abdominal adiposity in U.S. adults: prevalence and trends, 1960-2000. *Prev Med* 2004; 39: 197-206.
7. Lao TT, Ho LF, Chan BC, Leung WC. Maternal age and prevalence of gestational diabetes mellitus. *Diabetes Care* 2006; 29: 948-9.
8. Levy A, Wiznitzer A, Holcberg G, Mazor M, Sheiner E. Family history of diabetes mellitus as an independent risk factor for macrosomia and cesarean delivery. *J Matern Fetal Neonatal Med* 2010; 23: 148-52.
9. Abadi KK, Jama AH, Legesse AY, Gebremichael AK. Prevalence of hypothyroidism in pregnancy and its associations with adverse pregnancy outcomes among pregnant women in a general hospital: a cross sectional study. *Int J Womens Health* 2023; 15: 1481-90.
10. Mincer DL, Jialal I. Hashimoto Thyroiditis. 2023 Jul 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
11. Lee J, Lee NK, Moon JH. Gestational diabetes mellitus: mechanisms underlying maternal and fetal complications. *Endocrinol Metab* 2025; 40: 10-25.
12. Mirrahimov E, Bektasheva E, Isakova J, et al. Association of leptin receptor gene Gln223Arg polymorphism with insulin resistance and hyperglycemia in patients with metabolic syndrome. *Arch Med Sci* 20: 54-60.
13. Tyagi S, Kaur M, Yadav A, Gupta R. Genetic predisposition to thyroid dysfunction: a case-control study investigating TSHR gene polymorphism (rs2268458) in Indians. *Egypt J Med Hum Genet* 2024; 25: 129.
14. Ortega-Contreras B, Armella A, Appel J, et al. Pathophysiological role of genetic factors associated with gestational diabetes mellitus. *Front Physiol* 2022; 13: 769924.
15. Williams AT, Chen J, Coley K, et al. Genome-wide association study of thyroid-stimulating hormone highlights new genes, pathways and associations with thyroid disease. *Nat Commun* 2023; 14: 6713.
16. Ludvik AE, Pusec CM, Priyadarshini M, et al. HKDC1 is a novel hexokinase involved in whole-body glucose use. *Endocrinology* 2016; 157: 3452-61.
17. Pusec CM, De Jesus A, Khan MW, et al. Hepatic HKDC1 expression contributes to liver metabolism. *Endocrinology* 2019; 160: 313-30.
18. Khan MW, Priyadarshini M, Cordoba-Chacon J, Becker TC, Layden BT. Hepatic hexokinase domain containing 1 (HKDC1) improves whole body glucose tolerance and insulin sensitivity in pregnant mice. *Biochim Biophys Acta Mol Basis Dis* 2019; 1865: 678-87.
19. Zapater JL, Lednovich KR, Layden BT. The role of hexokinase domain containing protein-1 in glucose regulation during pregnancy. *Curr Diab Rep* 2021; 21: 27.
20. Kanthimathi S, Liju S, Laasya D, Anjana RM, Mohan V, Radha V. Hexokinase domain containing 1 (HKDC1) gene variants and their association with gestational diabetes mellitus in a South Indian population. *Ann Hum Genet* 2016; 80: 241-5.
21. Khan MW, Ding X, Cotler SJ, Clarke M, Layden BT. Studies on the tissue localization of HKDC1, a putative novel fifth hexokinase, in humans. *J Histochem Cytochem* 2018; 66: 385-92.
22. International Association of Diabetes and Pregnancy Study Groups Consensus Panel; Metzger BE, Gabbe SG, Persson B, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. *Diabetes Care* 2010; 33: 676-82.
23. Solha STG, Mattar R, Teixeira PFDS, et al. Screening, diagnosis and management of hypothyroidism in pregnancy. *Rev Bras Ginecol Obstet* 2022; 44: 999-1010.
24. Tan YX, Hu SM, You YP, Yang GL, Wang W. Replication of previous genome-wide association studies of HKDC1, BACE2, SLC16A11 and TMEM163 SNPs in a gestational diabetes mellitus case-control sample from Han Chinese population. *Diabetes Metab Syndr Obes* 2019; 12: 983-9.
25. Popova PV, Klyushina AA, Vasilyeva LB, et al. Association of common genetic risk variants with gestational diabetes mellitus and their role in GDM prediction. *Front Endocrinol* 2021; 12: 628582.
26. Krishnan M, Murphy R, Okesene-Gafa KAM, et al. The Pacific-specific CREBRF rs373863828 allele protects against gestational diabetes mellitus in Māori and Pacific women with obesity. *Diabetologia* 2020; 63: 2169-76.
27. Burden HJ, Adams S, Kulatea B, et al. The CREBRF diabetes-protective rs373863828-A allele is associated with enhanced early insulin release in men of Māori and Pacific ancestry. *Diabetologia* 2021; 64: 2779-89.
28. Kraus AU, Penna-Martinez M, Shoghi F, Seidl C, Meyer G, Badenhop K. HLA-DQB1 position 57 defines susceptibility to isolated and polyglandular autoimmunity in adults: interaction with gender. *J Clin Endocrinol Metab* 2019; 104: 1907-16.
29. Kaykhaei M, Moghadam H, Dabiri S, et al. Association of CTLA4 (rs4553808) and PTPN22 (rs2476601) gene

- polymorphisms with Hashimoto's thyroiditis disease: a case-control study and an In-silico analysis. *Meta Gene* 2020; 24: 100693.
30. Wei Y, Zhen J, Hu L, et al. Genome-wide association studies of thyroid-related hormones, dysfunction, and autoimmunity among 85,421 Chinese pregnancies. *Nat Commun* 2024; 15: 8004.
 31. Zapater JL, Lednovich KR, Khan MW, Pusec CM, Layden BT. Hexokinase domain-containing protein-1 in metabolic diseases and beyond. *Trends Endocrinol Metab* 2022; 33: 72-84.